Funder: Cancer Research Institute
Due Dates (Anticipated): January 15, 2026 (Full application) | Early March 2026 (Interview notification) | July 1, 2026 (Earliest award start)
Funding Amounts: Up to $1.25 million total ($250,000/year for 5 years); no indirect costs allowed.
Summary: Flexible, long-term funding for mid-career scientists to pursue innovative, high-risk research in cancer immunotherapy.
Key Information: Award is to the investigator, not project-specific; 80% research effort required; no for-profit institutions.